Valneva has already made 5 deals this year licensing the use of its EB66 cell line to develop new vaccines, and now, it is adding two more to the list.
Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.
MorphoSys has moved to add targets for its immuno-oncology arsenal. The agreement sees MorphoSys gain access to tumor-associated peptides discovered by its compatriot Immatics Biotechnologies in exchange for some of its antibodies, with both companies paying out milestones as their respective programs advance.
Japan's R-Tech Ueno, which faced a clinical setback this year in ophthalmology even as it sought wider opportunities in the area, has seen U.S.-based Sucampo launch a tender for the firm valued at $278 million overall after the founders agreed to sell their holdings.
Swedish contractor Recipharm inked a deal with Israeli biotech RedHill Biopharma to produce the company's leading drug candidate for clinical trials and an expected commercial launch.
Earlier this year, GE Healthcare CEO Jeff Immelt cited hospitals as a potentially lucrative source of growth for the company, pointing to a shift toward major contracts amid healthcare reform. Now, the company is taking a big step in that direction, inking a deal with Philadelphia's Temple University Health System to improve the medical center's radiology technology while helping it cut costs.
Sequenom has already made waves with its noninvasive prenatal diagnostic, revealing earlier this year that its technology could uncover signs of cancer in pregnant women. Now, the company is moving forward with its new liquid biopsy test, teaming up with the UC San Diego Moores Cancer Center to use its tool to monitor cancer patients and match them with a suitable therapy.
Harpreet Singh, the CSO and co-founder of Germany's Immatics Biotechnologies, has been splitting his time between Germany and Houston in order to set up a new biotech company that will collaborate with some top researchers at MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline.
Hospira and healthcare IT firm Cerner are joining forces to develop the companies' infusion pump information platform, building on previous efforts to better integrate Hospira's infusion pumps with Cerner's electronic medical record systems.
AstraZeneca has struck its fourth immuno-oncology deal in as many weeks. The latest deal in the flurry of activity sees AstraZeneca hook up with Peregrine Pharmaceuticals to add another study to the burgeoning list of PD-L1 checkpoint inhibitor combination trials.